XNAS · CUE
-4.49% · -$1.04 · Vol 133.2K
Market closed · last close 4:00 PM ET · price as of 17:29:38 ET
Cue Biopharma, Inc.

Cue Biopharma, Inc.

PHARMACEUTICAL PREPARATIONS
$22.10
Card
Relationship Map

Follow $CUE

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $CUE by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
CUE
Cue Biopharma, Inc.
Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

45/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CUE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CUE catalysts
About Cue Biopharma, Inc.
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
29
Country
US

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$22.92
Day high
$23.10
Day low
$22.27
Previous close
$23.14
52W high
$37.84
-41.60% from high
52W low
$5.31
52% of range
Market cap
$168.1M
Beta
1.60
Shares out
7.3M
Volume
133.2K
0.38× rel vol
Avg volume
351.7K
VWAP
$22.66
Price history computed in-house
1W
-12.48%
1M
-26.33%
3M
-39.91%
1Y
-14.14%
YTD
+141.21%
SMA 50 $28.24 · below
SMA 200 $20.28 · above
52W position 52%

CUE overview

Veridion Score
45
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CUE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CUE Form 4 filings
Public disclosures

Congress activity in CUE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

CUE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CUE in this window.
Lobbying spend

CUE lobbying filings, year to date.

Registered lobbying filings matched to Cue Biopharma, Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CUE in this window.
Loading news for CUE
Analyst ratings
Sovereign unlock shows live analyst consensus for CUE.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.